Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that the preclinical result of IBI319 was published in Nature Communications. The publication entitled, "Cancer immune therapy with PD-1-dependent...
Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections
BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /PRNewswire/ -- Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Bugworks Announces...
BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston
BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration. BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then conducted gain-of-function studies and discovered the over-expressed miRNA may be an underlying cause of the disease, deciding to develop...
Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity
The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo The trial also showed that 77.1% of study participants who received Wegovy™ lost at least 5% of their body weight, compared to 34.4% of those who...
PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline
Study shows PromarkerD is significantly better than current standard of care tests eGFR and ACR for predicting future decline in kidney function in patients with type 2 diabetes PromarkerD correctly identified 84% of patients with normal kidney function that went on to experience kidney function decline that would be...
CIIE 2021: Offering new opportunities for COVID recovery
SHANGHAI, Nov. 5, 2021 /PRNewswire/ -- On Nov 5, the China International Import Expo (CIIE), the first national-level import-themed professional trade fair nowadays in the world, successfully opened at the National Exhibition and Convention Center (Shanghai). Initiated by the Chinese government since 2018, the CIIE continues to serve as a significant platform...
ASH 2021 | Ascentage Pharma to Release Latest Data from Two Studies of Its Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a Chinese Study Demonstrating Complete Response
SUZHOU, China, and ROCKVILLE, MD., Nov. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on six studies of the company's three drug candidates (olverembatinib , lisaftoclax , and pelcitoclax ) have been...
ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at...
SUZHOU, China and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on three clinical trials of the company's novel drug candidate, olverembatinib (HQP1351), have been selected for poster presentations...
New Data at ASH 2021 Reinforces the Strength of Servier’s Hematology Portfolio
First Phase 3 results from the AGILE trial in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation show improved event-free survival and various secondary outcomes, including complete remission, overall survival and objective response rate, with ivosidenib tablets (TIBSOVO®) in combination with azacitidine compared to azacitidine plus placebo Updated survival...
Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO GAITHERSBURG, Md., Nov. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling submission to the...
